According to EyePoint Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.24. At the end of 2024 the company had a P/S ratio of 11.4.
Year | P/S ratio | Change |
---|---|---|
2024 | 11.4 | -53.7% |
2023 | 24.5 | 751.28% |
2022 | 2.88 | -74.35% |
2021 | 11.2 | 288.55% |
2020 | 2.89 | -65.29% |
2019 | 8.33 | -90.41% |
2018 | 86.9 | 363.72% |
2017 | 18.7 | 120.42% |
2016 | 8.50 | -89.71% |
2015 | 82.6 | 1820.76% |
2014 | 4.30 | -91.29% |
2013 | 49.4 | 316.17% |
2012 | 11.9 | 227.12% |
2011 | 3.63 | -34.38% |
2010 | 5.53 | 10.37% |
2009 | 5.01 | 163.24% |
2008 | 1.90 | 147.64% |
2007 | 0.7685 | 103.1% |
2006 | 0.3784 | -99.75% |
2005 | 154 |